Alcobra Ltd. to Participate in Piper Jaffray 27th Annual Healthcare Conference

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. SPY
2. KBH
3. PATH
4. USO
5. AZO
6. QQQ
7. META
8. ORCL
9. RCL
10. ONON

November 24, 2015 8:01 AM EST

TEL AVIV, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference.

Piper Jaffray 27th Annual Healthcare Conference
Panel Title: "Underdiscovered NeuroInnovators"
Date: Wednesday, December 2
Time: 10:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Tomer Berkovitz, CFO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference. 

CONTACT: U.S. Investor Contacts
         LifeSci Advisors, LLC
         Michael Rice
         646-597-6979
         [email protected]

         Media Inquiries
         Sam Brown, Inc.
         Mike Beyer
         312-961-2502
         [email protected]

         Israel Investor Contact:
         Alcobra Investor Relations
         Debbie Kaye
         +972-72 2204661
         [email protected]

Source: Alcobra Ltd.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

Piper Jaffray